We've talked about the stellar "Baby Biotech" I'm going to update you on today. It's actually the first stock I ever recommended in Private Briefing, back in 2011.
At the time, you could buy it for less than nine bucks a share – $8.60.
The innovative firm has packed on peak gains of more than 1,003% since then, hitting a high of $94.88 a share.
Now, I usually keep choice recommendations like this between myself and my paid-up subscribers. Not because I'm sentimental about the first stock pick we looked at together, but because it's only fair.
But over the years, the gains have simply grown too huge to keep a lid on.
So in the summer of 2016, almost at the exact moment it was making new all-time highs, I recommended this company to Money Morning Members.
We've enjoyed market-crushing peak gains of more than 37% since then.
In point of fact, virtually every time we've published an updated recommendation, first in Private Briefing and then later in Money Morning, for these shares, the predicted catalyst we've spotted has exploded and big gains have followed.
And in any case – whether this stock has delivered you "ten bagger"-style gains already, or you're just getting used to the idea of years of triple-digit profits from one stock – you're going to love what I see coming just around the corner for this company…
There's an "Uplisting" Coming Soon
I updated everyone on the massive profit potential in Galapagos NV's (Nasdaq ADR: GLPG) flagship JAK inhibitor drug, filgotinib, just a few weeks ago.
But, incredibly, this company is at it again. This time on the financial front.
The Mechelen, Belgium-based drugmaker recently announced plans for a global offering of common stock.
But there's a cool, potentially very lucrative twist…
As part of the offering, Galapagos has asked the U.S. Securities and Exchange Commission (SEC) for permission to offer shares here in the U.S. market in the form of "American Depositary Shares" (ADS) that will supplant its current over-the-counter (OTC)/American Depository Receipt (ADR) shares.
This isn't the first time we've seen this sort of ADS scheme from this play.
Back in 2015, the biotech firm used the same method to "uplist" to the Nasdaq stock market under the ticker GLPG – a move that netted the firm more than $210 million.
About the Author
Before he moved into the investment-research business in 2005, William (Bill) Patalon III spent 22 years as an award-winning financial reporter, columnist, and editor. Today he is the Executive Editor and Senior Research Analyst for Money Morning at Money Map Press. With his latest project, Private Briefing, Bill takes you "behind the scenes" of his established investment news website for a closer look at the action. Members get all the expert analysis and exclusive scoops he can't publish... and some of the most valuable picks that turn up in Bill's closed-door sessions with editors and experts.